Details of the Drug Reposition

General Information of This Drug (ID: DMS2J0Z)

Drug Name
Pexidartinib   DMS2J0Z
Synonyms PLX-3397
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Tenosynovial giant cell tumour DISYGQZI 2F7B Approved [1]
------------------------------------------------------------------------------------
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alzheimer disease DISF8S70 8A20 Phase 3 [2]
Pigmented villonodular synovitis DISWK23O FA27.1 Phase 3 [3]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neurofibromatosis type 1 DIS53JH9 LD2D.10 Phase 1/2 [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT02371369) PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)